Product Name :
BW 245C
Description:
BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.
CAS:
72814-32-5
Molecular Weight:
368.47
Formula:
C19H32N2O5
Chemical Name:
7-[(4S)-3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid
Smiles :
OC(=O)CCCCCC[C@H]1C(=O)NC(=O)N1CCC(O)C1CCCCC1
InChiKey:
ZIDQIOZJEJFMOH-VYRBHSGPSA-N
InChi :
InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)/t15-,16?/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.MDTF References
Shelf Life:
≥12 months if stored properly.Penicillin-Streptomycin NF-κB
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:35045880
Additional information:
BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.|Product information|CAS Number: 72814-32-5|Molecular Weight: 368.47|Formula: C19H32N2O5|Chemical Name: 7-[(4S)-3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid|Smiles: OC(=O)CCCCCC[C@H]1C(=O)NC(=O)N1CCC(O)C1CCCCC1|InChiKey: ZIDQIOZJEJFMOH-VYRBHSGPSA-N|InChi: InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)/t15-,16?/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|BW245C (0.01-1 μM) suppresses TGF-β-induced collagen secretion in a dose-dependent manner in Th2 cells. BW245C (0.01-1 μM) also increases intracellular cAMP in lung fibroblasts. BW245C (0.1-3 μmol/L) dose-dependently increases transendothelial electrical resistance and decreases the FITC-dextran permeability of human umbilical vein endothelial cells. BW245C (0.3 μmol/L) increases the intracellular cAMP level and subsequent protein kinase A (PKA) activity.|In Vivo:|BW245C (0.02, 0.2, and 2.0 mg/kg) in WT mice results in a significant increase in CBF, but this effect of this treatment is absent in DP1−/− mice. BW245C attenuates functional deficits after stroke. BW245C significantly reverses these conditions that neurologic deficit is significantly augmented, whereas locomotor activity is significantly reduced after stroke in WT mice. BW245C (0.2 mg/kg) injection 1 h after stroke results in a significant decrease in brain infarction in WT mice, whereas the effect of this treatment is not observed in DP1−/− mice. BW245C improves CBF during and after stroke. BW245C results in significantly prolonged bleeding compared with the vehicle-treated group. BW 245C (100 nM) does not significantly increase MBP-positive eosinophils in esophageal epithelium in OVA-sensitized guinea pigs.|Products are for research use only. Not for human use.|
